Viralytics remains an outstanding prospect in the field of immunotherapy for the treatment of various cancers.
The key clinical highlights from 2017 included:
First results from the keynote 200 trial which showed strong recruitment in both lung and bladder cancer patients. 64 of 80 patients are now recruited. Of the patients to reach the first evaluation point:
5 of 6 bladder patients have shown responses;
3 of 6 non small cell lung cancer patients have responded including one patient with a near complete response.
Success in the keynote 200 trial would transform the company from being merely able to address late stage melanoma into a vastly different proposition. Pending the results of this trial, Cavatak may potentially be combined with checkpoint inhibitors to treat a vastly expanded group of cancers and therefore increasing its potential value.
Investigators will be watching for this key data as results emerge during the course of 2018. Cavatak has achieved outstanding results in late stage melanoma patients who have shown long duration of response that are suggestive of an improvement in overall survival. Should these results be repeated in the keynote 200 trial, the likelihood of a substantial offer for VLA increases significantly.
VLA remains well capitalised with cash of ~$30m and an exceptionally supportive shareholder base amongst US based institutions as well as local institutional investors.
Speculative Buy
VLA Price at posting:
69.0¢ Sentiment: Buy Disclosure: Held
